Search hospitals > Connecticut > Waterbury
Smilow Cancer Hospital-Waterbury Care Center
Claim this profileWaterbury, Connecticut 06708
Global Leader in Thyroid Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Stomach Cancer
94 reported clinical trials
39 medical researchers
Summary
Smilow Cancer Hospital-Waterbury Care Center is a medical facility located in Waterbury, Connecticut. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Breast cancer, Stomach Cancer and other specialties. Smilow Cancer Hospital-Waterbury Care Center is involved with conducting 94 clinical trials across 254 conditions. There are 39 research doctors associated with this hospital, such as Farzana Pashankar, Alessandro Santin, Amer M. Zeidan, and Joseph W. Kim, MD.Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Farzana PashankarYale University7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
33 reported clinical trials
78 drugs studied
Alessandro SantinSmilow Cancer Hospital at Yale New Haven5 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
17 reported clinical trials
25 drugs studied
Amer M. ZeidanYale Cancer Center4 years of reported clinical research
Expert in Myelodysplastic Syndrome
Expert in T-Lymphoblastic Leukemia/Lymphoma
17 reported clinical trials
27 drugs studied
Joseph W. Kim, MDYale University8 years of reported clinical research
Studies Thyroid Cancer
Studies Prostate Cancer
14 reported clinical trials
27 drugs studied
Clinical Trials running at Smilow Cancer Hospital-Waterbury Care Center
Breast Cancer
Lung Cancer
Thyroid Cancer
Breast cancer
Multiple Myeloma
Bladder Cancer
Non-Small Cell Lung Cancer
Uterine Cancer
Gallbladder Cancer
Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Smilow Cancer Hospital-Waterbury Care Center?
Smilow Cancer Hospital-Waterbury Care Center is a medical facility located in Waterbury, Connecticut. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Breast cancer, Stomach Cancer and other specialties. Smilow Cancer Hospital-Waterbury Care Center is involved with conducting 94 clinical trials across 254 conditions. There are 39 research doctors associated with this hospital, such as Farzana Pashankar, Alessandro Santin, Amer M. Zeidan, and Joseph W. Kim, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.